Phase 1 study of DS-1205c combined with gefitinib for EGFR mutation-positive non-small cell lung cancer.

Koichi Goto, Yoshimasa Shiraishi,Haruyasu Murakami,Hidehito Horinouchi,Ryo Toyozawa,Masayuki Takeda,Makiko Uno,Nigel Crawford,Joseph McGill,Takeshi Jimbo,Masato Ishigami,Gensuke Takayama, Shintaro Nakayama,Shoichi Ohwada,Makoto Nishio

Cancer medicine（2023）

引用 1|浏览34

暂无评分

摘要

DS-1205c was generally safe and well tolerated at all dose levels, but the safety profile of ≤800 mg BID was more favorable than 1200 mg BID. The recommended dose for dose-expansion cohorts of DS-1205c in combination therapy with gefitinib was 800 mg BID.

查看译文

关键词

AXL inhibitor,DS-1205,gefitinib,non-small cell lung cancer,phase I clinical trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要